Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10)

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 3, 2005, Pages 788-794

  Konski, Andre ^a   Sherman, Eric ^a   Krahn, Murray ^b,c   Bremner, Karen ^c   Beck, J Robert ^a   Watkins Bruner, Deborah ^a   Pilepich, Michael ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deprivation; Economic analysis; Prostate cancer

Indexed keywords

BIOLOGICAL ORGANS; COST EFFECTIVENESS; DISEASE CONTROL; HORMONES; MARKOV PROCESSES; MATHEMATICAL MODELS; MONTE CARLO METHODS; ONCOLOGY; PATIENT MONITORING; PROBABILITY;

ANDROGEN DEPRIVATION; CLINICAL TRIALS; ECONOMIC ANALYSIS; PROSTATE CANCER;

RADIOTHERAPY;

ANTIANDROGEN; FLUTAMIDE; GOSERELIN;

ADVANCED CANCER; ARTICLE; CALCULATION; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONTE CARLO METHOD; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HUMANS; MALE; MARKOV CHAINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY;

EID: 25844493090     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.03.010     Document Type: Article

References (23)

1. W.U. Shipley, J.D. Lu, M.V. Pilepich Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy A secondary analysis of the randomized protocol RTOG 86-10 Int J Radiat Oncol Biol Phys 54 2002 1302 1310
2. E.M. Horwitz, K. Winter, G.E. Hanks Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy Int J Radiat Oncol Biol Phys 49 2001 947 956
3. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
4. M.V. Pilepich, J.M. Krall, M. al-Sarraf Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma A randomized comparative trial of the Radiation Therapy Oncology Group Urology 45 1995 616 623
5. M.V. Pilepich, R. Caplan, R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
6. G.E. Hanks, T.R. Pajak, A. Porter Phase III Trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
7. S.J. Feigenberg, A.L. Hanlon, E.M. Horwitz Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy Int J Radiat Oncol Biol Phys 57 2003 S176
8. F.A. Sonnenberg, J.R. Beck Markov models in medical decision making A practical guide Med Decis Making 13 1993 322 338
9. J.R. Beck, S.G. Parker The Markov process in medical prognosis Med Decis Making 3 1983 419 458
10. D. Naimark, M.D. Krahn, G. Naglie Primer on medical decision analysis Part 5 - working with Markov processes Med Decis Making 17 1997 152 159
11. M.V. Pilepich, K. Winter, M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
12. M.G. Oefelein, P.K. Agarwal, M.I. Resnick Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era J Urol 171 2004 1525 1528
13. C. Fleming, J.H. Wasson, P.C. Albertsen A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team JAMA 269 1993 2650 2658
14. K. Kuntz, M. Weinstein Modelling in economic evaluation M. Drummond A. McGuire Merging theory with practice. Economic evaluation in health care 2001 Oxford University Press New York 141 171
15. A.H. Briggs Handling uncertainty in economic evaluation and presenting the results M. Drummond A. McGuire Economic evaluation in health care Merging theory with practice 2001 Oxford University Press New York 172 214
16. J.B. Owen, P.W. Grigsby, T.M. Caldwell Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04 Int J Radiat Oncol Biol Phys 49 2001 633 639
17. J. Lipscomb, M.C. Weinstein, G.W. Torrance Time preference M. Gold J.E. Siegel L.B. Russell Cost-effectiveness in health and medicine 1996 Oxford University Press New York 214 235
18. N.Y. Piper, L. Kusada, R. Lance Adenocarcinoma of the prostate An expensive way to die Prostate Cancer Prostatic Dis 5 2002 164 166
19. M. Krahn, P. Ritvo, J. Irvine Patient and community preferences for outcomes in prostate cancer Implications for clinical policy Med Care 41 2003 153 164
20. C.L. Bennett, D. Matchar, D. McCrory Cost-effective models for flutamide for prostate carcinoma patients Are they helpful to policy makers? Cancer 77 1996 1854 1861
21. N. Neymark, I. Adriaenssen, T. Gorlia Estimating survival gain for economic evaluations with survival time as principal endpoint A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer Health Econ 11 2002 233 248
22. B.E. Hillner, D.G. McLeod, E.D. Crawford Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer Urology 45 1995 633 640
23. A.M. Bayoumi, A.D. Brown, A.M. Garber Cost-effectiveness of androgen suppression therapies in advanced prostate cancer J Natl Cancer Inst 92 2000 1731 1739